43rd Annual William K. Ishmael Lectureship


Date & Location
Thursday, October 5, 2017 5:00 PM - Friday, October 6, 2017 2:00 PM   OMRF Wileman Auditorium, 825 NE 13th Street, Oklahoma City, OK

Specialties
All specialties, APRN/PA, Family Medicine, General Medicine, Geriatrics, Internal Medicine, Nurse Practitioners, Orthopaedics, Pediatrics, Pharmacist, Physician Assistants, Primary Care Physicians

Overview
The 43rd Annual William K. Ishmael Lectureship is a continuing medical education event open to all physicians, researchers and those in the medical community focused in rheumatology, orthopedics, family medicine, internal medicine and immunology. The activity begins with dinner on Thursday, October 5th and continues throughout the day on Friday, October 6th. Lectures provide specific updates in diagnosis, treatment, and pathogenesis of rheumatic diseases taught by experts in their respective fields.  During breakfast and lunch attendees will have the opportunity to network.

Objectives
Upon completion of this activity, participants will improve their competence and performance by being able to:
  1. Discuss the new treatment options for antineutrophil cytoplasmic antibodies (ANCA) vasculitis.
  2. Discuss the diagnostic and treatment options for thrombotic microangiopathy.
  3. Discuss the new diagnostic and therapeutic options in for juvenile idiopathic arthritis.
  4. Discuss the new diagnostic and treatment options for inflammatory myositis.
  5. Discuss the complications that occur with rheumatoid arthritis.

Registration
On or Before October 4, 2017
$100 Physicians
$50 Other Healthcare Professionals

After October 4, 2017
$125 Physicians
$75 Other Healthcare Professionals

Cancellation Fee:  $25
Written notification of cancellation must be postmarked on or before October 5, 2017
No registration refunds will be made after October 5, 2017

Accreditation

The University of Oklahoma College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The University of Oklahoma College of Medicine designates this live activity for a maximum of 5.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


Conflict Resolution Statement

The University of Oklahoma College of Medicine, Office of Continuing Professional Development has reviewed this activity’s speaker and planner disclosures and resolved all identified conflicts of interest, if applicable.

Planning Committee Members
 
Mary Beth Humphrey, MD, PhD - Course Director
Elizabeth S. Taylor-Albert, MD
Alan Martin, MD
Latisha Heinlen, MD, PhD
Nicole L. Lung - Course Contact

Learning Objectives

Upon completion of this activity, participants will improve their competence and performance by being able to:

  1. Discuss the new treatment options for Antineutrophil cytoplasmic antibodies (ANCA) vasculitis.
  2. Discuss the diagnostic and treatment options for thrombotic microangiopathy.
  3. Discuss the new diagnostic and therapeutic options in for juvenile idiopathic arthritis.
  4. Discuss the new diagnostic and treatment options for inflammatory myositis.
  5. Discuss the complications that occur with rheumatoid arthritis.

Nondiscrimination Statement

The University of Oklahoma, in compliance with all applicable federal and state laws and regulations does not discriminate on the basis of race, color, national origin, sex, sexual orientation, genetic information, gender identity, gender expression, age, religion, disability, political beliefs, or status as a veteran in any of its policies, practices, or procedures. This includes, but is not limited to: admissions, employment, financial aid, and educational services.

The University of Oklahoma is an equal opportunity institution. www.ou.edu/eoo.

Accommodation Statement

Accommodations on the basis of disability are available by contacting Nicole Lung at (405) 271-2330 or Nicole-Lung@ouhsc.edu as soon as possible.

Acknowledgement of Commercial and In-Kind Support

Commercial support 

is financial, or in-kind, contributions given by a commercial interest, which is used to pay all or part of the costs of a CME activity. A commercial interest is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients.

Appropriate acknowledgement of all commercial and in-kind support will be given at the time of the educational activity.

Disclaimer Statement

Statements, opinions and results of studies contained in the program are those of the presenters and authors and do not reflect the policy or position of the Board of Regents of the University of Oklahoma (“OU”) nor does OU provide any warranty as to their accuracy or reliability.

Every reasonable effort has been made to faithfully reproduce the presentations and material as submitted. However, no responsibility is assumed by OU for any claims, injury and/or damage to persons or property from any cause, including negligence or otherwise, or from any use or operation of any methods, products, instruments or ideas contained in the material herein.

Policy on Faculty and Presenters Disclosure

It is the policy of the University of Oklahoma, College of Medicine that the faculty and presenters disclose real or apparent conflicts of interest relating to the topics of this educational activity, and also disclose discussions of unlabeled/unapproved uses of drugs or devices during their presentation(s).